Myopridin (Pridinol Mesilate)

Pridinol mesilate, the active ingredient in Myopridin, is a muscle relaxant presented as an injectable solution for intramuscular use. It reduces skeletal muscle tone and is employed to treat muscle spasm and related skeletal muscle disorders in adult patients.

GNH USA supplies Myopridin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, including temperature‑controlled shipping where required. This ensures product integrity from manufacturing to end‑user.

Pridinol mesilate is indicated for conditions involving excessive skeletal muscle tone and related spasms. - Muscle spasm: alleviates painful involuntary contractions by reducing muscle tone. - Skeletal muscle disorders: improves mobility and comfort in patients with chronic muscle hypertonicity. - Acute musculoskeletal pain: provides rapid relief through central anticholinergic action on muscle fibers. - Post‑operative muscle stiffness: facilitates early physiotherapy by decreasing tone. - Spasticity in neurological conditions: reduces exaggerated reflexes and improves functional movement.

Pridinol mesilate may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Injection site pain: mild discomfort or tenderness at the intramuscular injection site. - Dizziness: transient sensation of light‑headedness or imbalance. - Dry mouth: reduced salivation leading to throat dryness. - Nausea: mild gastrointestinal upset. - Headache: mild to moderate head discomfort. - Fatigue: feeling of tiredness or reduced energy. Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy with rash, swelling, and breathing difficulty. - Respiratory depression: marked reduction in breathing rate requiring medical attention. - Cardiac arrhythmia: irregular heart rhythm that may need monitoring. - Seizure: rare occurrence of convulsive activity. - Hypotension: sudden drop in blood pressure causing dizziness.

When using Pridinol mesilate, certain precautions should be observed to minimize risk and ensure safe administration. - Assess renal function: evaluate kidney status before initiating therapy, especially in patients with known impairment. - Monitor anticholinergic effects: watch for dry mouth, blurred vision, or urinary retention during treatment. - Use caution in elderly: older adults may be more sensitive to central nervous system effects. - Avoid in known hypersensitivity: discontinue immediately if allergic reactions such as rash or swelling occur. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Pridinol mesilate may interact with a variety of concomitant medications, potentially altering its therapeutic effect or increasing the likelihood of adverse reactions; careful review of a patient’s drug regimen is recommended before prescribing. Major Interactions (Avoid): - MAO inhibitors: risk of exaggerated anticholinergic and hypertensive reactions. - Other central anticholinergics: additive sedation and dry‑mouth effects. - CNS depressants (e.g., benzodiazepines, opioids): enhanced CNS depression and respiratory compromise. - Tricyclic antidepressants: may increase anticholinergic load and cardiac effects. - Antipsychotics: potential additive sedation and orthostatic hypotension. Moderate Interactions (Monitor Closely): - Beta‑blockers: possible alteration of heart rate response. - Antihistamines: increased anticholinergic burden may worsen dryness. - Alcohol: can potentiate CNS depression and dizziness.